文献速递银屑病与炎症性皮肤病

ADAM10/17介导的LAG3切割在银屑病免疫抑制受损中的作用

Role of ADAM10/17-Mediated Cleavage of LAG3 in the Impairment of Immunosuppression in Psoriasis.
PubMed 文献 · J Invest Dermatol · 2024-11-20

本研究探讨银屑病中LAG3表达下降的机制。发现银屑病CD4 T细胞和调节性T细胞中LAG3表达降低,与ADAM10/17介导的蛋白切割增强有关;IL-17A通过FOXM1上调ADAM10/17,促进LAG3切割。ADAM10/17抑制剂GW280264X可改善银屑病样小鼠模型和LPS诱导的炎症,提示靶向ADAM10/17的治疗潜力。

要点

  • 银屑病中CD4 T细胞和Treg的LAG3表达降低,与免疫抑制受损相关。
  • IL-17A通过FOXM1上调ADAM10/17,促进LAG3切割。
  • ADAM10/17抑制剂GW280264X可改善银屑病样小鼠模型和LPS诱导的炎症。

核心结论

  • 银屑病中ADAM10/17介导的LAG3切割增强导致免疫抑制受损,靶向ADAM10/17具有治疗潜力。

研究设计与样本

  • 研究检测银屑病患者CD4 T细胞和Treg中LAG3表达,结合体外和体内IL-17A诱导模型及Jurkat细胞模型探索机制,并在银屑病样小鼠模型和LPS诱导炎症中评估ADAM10/17抑制剂效果。

主要发现

  • 银屑病与CD4 T细胞和Treg中LAG3表达降低相关。
  • LAG3水平下降与银屑病中上调的ADAM10/17介导的蛋白切割有关。
  • IL-17A可诱导ADAM10/17表达并触发LAG3切割,该过程通过激活FOXM1调控。
  • ADAM10/17抑制剂GW280264X对银屑病样小鼠模型和LPS诱导的炎症有改善作用。

临床怎么用

  • ADAM10/17-LAG3轴可能成为银屑病治疗的新靶点,ADAM10/17抑制剂或可改善银屑病炎症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite extensive research on immune activation regulatory mechanisms, studies on immune suppression in psoriasis are limited. LAG3, a newly identified immune checkpoint, plays a crucial role in modulating immune responses and maintaining T-regulatory cell function. However, its involvement in psoriasis is unclear. We show that psoriasis is associated with reduced LAG3 expression in CD4 T cells and T-regulatory cells. Further analysis revealed that the decline in LAG3 levels was linked to ADAM10/17-mediated proteolytic cleavage, which was upregulated in psoriasis. Clinical utilization of the IL-17A antagonist secukinumab, along with the in vivo and in vitro IL-17A-induced models, supported the potential of IL-17A to induce ADAM10/17 expression and trigger LAG3 cleavage. Through the Jurkat cell model, IL-17A was found to regulate ADAM10/17 expression by activating FOXM1. In addition, treatment with the ADAM10/17 inhibitor GW280264X showed ameliorative effects on psoriasis-like mouse models and lipopolysaccharide-induced inflammation. Collectively, the findings of this study uncover the immune regulatory role of the ADAM10/17-LAG3 axis in psoriasis and highlight the therapeutic potential of targeting ADAM10/17 for psoriasis treatment.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Yu Z, Tang X, Chen Z, et al. Role of ADAM10/17-Mediated Cleavage of LAG3 in the Impairment of Immunosuppression in Psoriasis. J Invest Dermatol. 2024. PMID: 39571889. doi:10.1016/j.jid.2024.10.606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。